JP2025027013A5 - - Google Patents
Info
- Publication number
- JP2025027013A5 JP2025027013A5 JP2024205131A JP2024205131A JP2025027013A5 JP 2025027013 A5 JP2025027013 A5 JP 2025027013A5 JP 2024205131 A JP2024205131 A JP 2024205131A JP 2024205131 A JP2024205131 A JP 2024205131A JP 2025027013 A5 JP2025027013 A5 JP 2025027013A5
- Authority
- JP
- Japan
- Prior art keywords
- application
- invention described
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462056569P | 2014-09-28 | 2014-09-28 | |
| US62/056,569 | 2014-09-28 | ||
| US201562129883P | 2015-03-08 | 2015-03-08 | |
| US62/129,883 | 2015-03-08 | ||
| JP2020207244A JP7168641B2 (ja) | 2014-09-28 | 2020-12-15 | 刺激性骨髄系細胞及び非刺激性骨髄系細胞の調節 |
| JP2022172033A JP7668257B2 (ja) | 2014-09-28 | 2022-10-27 | 刺激性骨髄系細胞及び非刺激性骨髄系細胞の調節 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022172033A Division JP7668257B2 (ja) | 2014-09-28 | 2022-10-27 | 刺激性骨髄系細胞及び非刺激性骨髄系細胞の調節 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025027013A JP2025027013A (ja) | 2025-02-26 |
| JP2025027013A5 true JP2025027013A5 (enExample) | 2025-09-30 |
Family
ID=55582160
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017516664A Active JP6811711B2 (ja) | 2014-09-28 | 2015-09-28 | 刺激性骨髄系細胞及び非刺激性骨髄系細胞の調節 |
| JP2020207244A Active JP7168641B2 (ja) | 2014-09-28 | 2020-12-15 | 刺激性骨髄系細胞及び非刺激性骨髄系細胞の調節 |
| JP2022172033A Active JP7668257B2 (ja) | 2014-09-28 | 2022-10-27 | 刺激性骨髄系細胞及び非刺激性骨髄系細胞の調節 |
| JP2024205131A Pending JP2025027013A (ja) | 2014-09-28 | 2024-11-26 | 刺激性骨髄系細胞及び非刺激性骨髄系細胞の調節 |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017516664A Active JP6811711B2 (ja) | 2014-09-28 | 2015-09-28 | 刺激性骨髄系細胞及び非刺激性骨髄系細胞の調節 |
| JP2020207244A Active JP7168641B2 (ja) | 2014-09-28 | 2020-12-15 | 刺激性骨髄系細胞及び非刺激性骨髄系細胞の調節 |
| JP2022172033A Active JP7668257B2 (ja) | 2014-09-28 | 2022-10-27 | 刺激性骨髄系細胞及び非刺激性骨髄系細胞の調節 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US10428143B2 (enExample) |
| EP (1) | EP3197495A4 (enExample) |
| JP (4) | JP6811711B2 (enExample) |
| KR (3) | KR102506663B1 (enExample) |
| CN (1) | CN106999585A (enExample) |
| AU (3) | AU2015319809B2 (enExample) |
| CA (1) | CA2961950A1 (enExample) |
| EA (1) | EA034921B1 (enExample) |
| IL (4) | IL283834B (enExample) |
| MX (2) | MX388410B (enExample) |
| WO (1) | WO2016049641A1 (enExample) |
| ZA (1) | ZA201701658B (enExample) |
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3081576T3 (pl) | 2013-12-12 | 2020-03-31 | Shanghai Hengrui Pharmaceutical Co., Ltd. | Przeciwciało anty pd-1, jego fragment wiążący antygen i ich zastosowanie medyczne |
| US20170240631A1 (en) | 2014-08-08 | 2017-08-24 | Alector Llc | Anti-trem2 antibodies and methods of use thereof |
| CA2961950A1 (en) * | 2014-09-28 | 2016-03-31 | The Regents Of The University Of California | Modulation of stimulatory and non-stimulatory myeloid cells |
| US20170151281A1 (en) | 2015-02-19 | 2017-06-01 | Batu Biologics, Inc. | Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer |
| CN109906381B (zh) * | 2016-08-31 | 2023-03-31 | 新加坡科技研究局 | 鉴别、靶向以及分离人树突细胞(dc)前体“前dc”的方法及其用途 |
| EP3516396B1 (en) | 2016-09-26 | 2024-11-13 | F. Hoffmann-La Roche AG | Predicting response to pd-1 axis inhibitors |
| EP4039260B1 (en) | 2017-02-07 | 2024-04-17 | Saitama Medical University | Cd62llow cd4+ t-cells for treating or preventing cancer |
| JOP20190248A1 (ar) | 2017-04-21 | 2019-10-20 | Amgen Inc | بروتينات ربط مولد ضد trem2 واستخداماته |
| CN107267555B (zh) * | 2017-05-27 | 2020-03-20 | 上海优卡迪生物医药科技有限公司 | 一种基于octs技术的恶性胶质瘤car-t治疗载体及其构建方法和应用 |
| DK3601358T5 (da) * | 2017-08-03 | 2024-09-02 | Alector Llc | Anti-trem2-antistoffer og fremgangsmåder til anvendelse deraf |
| WO2019032624A1 (en) * | 2017-08-08 | 2019-02-14 | Pionyr Immunotherapeutics, Inc. | COMPOSITIONS AND METHODS FOR DEACTIVATING TREM1-EXPRESSING MESHLOID CELLS |
| CA3079999A1 (en) * | 2017-11-07 | 2019-05-16 | The Board Of Regents Of The University Of Texas System | Targeting lilrb4 with car-t or car-nk cells in the treatment of cancer |
| CN111712518B (zh) | 2017-11-17 | 2025-03-25 | 默沙东有限责任公司 | 对免疫球蛋白样转录物3(ilt3)具有特异性的抗体及其用途 |
| KR102860409B1 (ko) * | 2017-12-12 | 2025-09-16 | 파이오니어 임뮤노테라퓨틱스, 인코퍼레이티드 | 항-trem2 항체 및 관련 방법 |
| CN108085393B (zh) * | 2018-01-31 | 2020-06-02 | 青岛泱深生物医药有限公司 | 肾透明细胞癌相关生物标志物及其应用 |
| SG11202007018QA (en) * | 2018-02-02 | 2020-08-28 | Oncoimmune Inc | Methods of selecting and designing safer and more effective anti-ctla-4 antibodies for cancer therapy |
| US20210261657A1 (en) * | 2018-06-21 | 2021-08-26 | Faron Pharmaceuticals Oy | Treatment of cancer with clever-1 inhibition in combination with pd-1/pd-l1 inhibitor |
| US12202855B2 (en) | 2018-06-25 | 2025-01-21 | Peter Maccallum Cancer Institute | Modified T cells and uses thereof |
| UY38407A (es) * | 2018-10-15 | 2020-05-29 | Novartis Ag | Anticuerpos estabilizadores de trem2 |
| EP3876977A1 (en) | 2018-11-06 | 2021-09-15 | The Regents Of The University Of California | Chimeric antigen receptors for phagocytosis |
| CA3120875A1 (en) * | 2018-12-11 | 2020-06-18 | Pionyr Immunotherapeutics, Inc. | Methods of using anti-trem2 antibodies |
| CN109609463B (zh) * | 2019-01-10 | 2022-07-01 | 中国医学科学院肿瘤医院 | 一种宫颈癌肿瘤原代细胞分离及培养方法 |
| US10836828B2 (en) | 2019-02-06 | 2020-11-17 | Pionyr Immunotherapeutics, Inc. | Anti-TREM1 antibodies and related methods |
| EP3927743A1 (en) | 2019-02-20 | 2021-12-29 | Denali Therapeutics Inc. | Anti-trem2 antibodies and methods of use thereof |
| TW202035702A (zh) | 2019-02-20 | 2020-10-01 | 學校法人埼玉醫科大學 | 評價藉由放射線治療之抗腫瘤免疫效果之末梢血液生物標記 |
| TW202035701A (zh) * | 2019-02-20 | 2020-10-01 | 學校法人埼玉醫科大學 | 用以預測於癌症免疫療法下之長期存活之方法及組合物 |
| US11013764B2 (en) | 2019-04-30 | 2021-05-25 | Myeloid Therapeutics, Inc. | Engineered phagocytic receptor compositions and methods of use thereof |
| WO2020247290A1 (en) * | 2019-06-04 | 2020-12-10 | Academia Sinica | Ligands targed to epidermal growth factor receptors and compositions for use in treating tumors |
| CA3147182A1 (en) * | 2019-08-13 | 2021-02-18 | Tohoku University | Novel immune checkpoint inhibitors and uses thereof |
| EP4025686A4 (en) | 2019-09-03 | 2023-09-13 | Myeloid Therapeutics, Inc. | Methods and compositions for genomic integration |
| CN110836974B (zh) * | 2019-11-07 | 2022-09-09 | 西安交通大学医学院第一附属医院 | Flt3lg蛋白在制备肺腺癌术后预后评估试剂或者试剂盒中的应用 |
| US10980836B1 (en) | 2019-12-11 | 2021-04-20 | Myeloid Therapeutics, Inc. | Therapeutic cell compositions and methods of manufacturing and use thereof |
| JP2023507110A (ja) | 2019-12-19 | 2023-02-21 | エヌジーエム バイオファーマシューティカルス，インコーポレーテッド | Ｉｌｔ３結合剤及びその使用方法 |
| KR20220131246A (ko) | 2020-01-13 | 2022-09-27 | 데날리 테라퓨틱스 인크. | 항-trem2 항체 및 이의 사용 방법 |
| IL272390A (en) | 2020-01-30 | 2021-08-31 | Yeda Res & Dev | Cancer treatment methods |
| WO2021209495A1 (en) * | 2020-04-14 | 2021-10-21 | Symphogen A/S | Anti-flt3 antibodies and compositions |
| WO2022057910A1 (en) * | 2020-09-17 | 2022-03-24 | I-Mab Biopharma Co., Ltd | Combination therapies targeting c5ar and pd-1/pd-l1 pathways |
| CA3197423A1 (en) | 2020-11-04 | 2022-05-12 | Daniel Getts | Engineered chimeric fusion protein compositions and methods of use thereof |
| US11617767B2 (en) | 2020-11-20 | 2023-04-04 | Simcere Innovation, Inc. | Armed dual CAR-T compositions and methods for cancer immunotherapy |
| GB2620502A (en) * | 2021-03-09 | 2024-01-10 | Mascarenhas Desmond | Modulation of mammalian cell lineage by synthetic immodulins |
| AU2022237618A1 (en) | 2021-03-17 | 2023-10-12 | Myeloid Therapeutics, Inc. | Engineered chimeric fusion protein compositions and methods of use thereof |
| JP2024518100A (ja) | 2021-05-11 | 2024-04-24 | マイエロイド・セラピューティクス，インコーポレーテッド | ゲノム組込みのための方法および組成物 |
| JP2024534976A (ja) * | 2021-09-08 | 2024-09-26 | ジョイント・ストック・カンパニー “バイオキャド” | Ｍｈｃタンパク質に基づくヘテロ二量体を含む二重特異性抗体 |
| WO2023076983A1 (en) | 2021-10-28 | 2023-05-04 | Gilead Sciences, Inc. | Pyridizin-3(2h)-one derivatives |
| JP7787991B2 (ja) | 2021-10-29 | 2025-12-17 | ギリアード サイエンシーズ， インコーポレイテッド | Ｃｄ７３化合物 |
| WO2023094436A1 (en) * | 2021-11-26 | 2023-06-01 | Technische Universität Dresden | Placental macrophages for cell therapy |
| AU2022419982A1 (en) | 2021-12-22 | 2024-06-06 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| WO2023122615A1 (en) | 2021-12-22 | 2023-06-29 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Ｐａｒｐ７抑制劑 |
| TW202346277A (zh) | 2022-03-17 | 2023-12-01 | 美商基利科學股份有限公司 | Ｉｋａｒｏｓ鋅指家族降解劑及其用途 |
| PE20250157A1 (es) | 2022-04-21 | 2025-01-22 | Gilead Sciences Inc | Compuestos de modulacion de kras g12d |
| CN119384415A (zh) | 2022-07-01 | 2025-01-28 | 吉利德科学公司 | Cd73化合物 |
| US20240254118A1 (en) | 2022-12-22 | 2024-08-01 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| KR20250167002A (ko) | 2023-04-11 | 2025-11-28 | 길리애드 사이언시즈, 인코포레이티드 | Kras 조절 화합물 |
| CN121079300A (zh) | 2023-04-21 | 2025-12-05 | 吉利德科学公司 | Prmt5抑制剂及其用途 |
| US20250042922A1 (en) | 2023-06-30 | 2025-02-06 | Gilead Sciences, Inc. | Kras modulating compounds |
| WO2025024811A1 (en) | 2023-07-26 | 2025-01-30 | Gilead Sciences, Inc. | Parp7 inhibitors |
| US20250066328A1 (en) | 2023-07-26 | 2025-02-27 | Gilead Sciences, Inc. | Parp7 inhibitors |
| TW202515919A (zh) | 2023-09-01 | 2025-04-16 | 比利時商艾托斯比利時公司 | 抗ｔｒｅｍ２抗體及使用方法 |
| US20250101042A1 (en) | 2023-09-08 | 2025-03-27 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| WO2025054530A1 (en) | 2023-09-08 | 2025-03-13 | Gilead Sciences, Inc. | Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds |
| WO2025096589A1 (en) | 2023-11-03 | 2025-05-08 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2025137640A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| WO2025245003A1 (en) | 2024-05-21 | 2025-11-27 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| GB9014932D0 (en) | 1990-07-05 | 1990-08-22 | Celltech Ltd | Recombinant dna product and method |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| EP0940468A1 (en) | 1991-06-14 | 1999-09-08 | Genentech, Inc. | Humanized antibody variable domain |
| FI941572A7 (fi) | 1991-10-07 | 1994-05-27 | Oncologix Inc | Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä |
| JPH05244982A (ja) | 1991-12-06 | 1993-09-24 | Sumitomo Chem Co Ltd | 擬人化ｂ−ｂ１０ |
| DE69334255D1 (de) | 1992-02-06 | 2009-02-12 | Novartis Vaccines & Diagnostic | Marker für Krebs und biosynthetisches Bindeprotein dafür |
| US7294331B2 (en) * | 1994-03-07 | 2007-11-13 | Immunex Corporation | Methods of using flt3-ligand in hematopoietic cell transplantation |
| DE19638745C2 (de) * | 1996-09-11 | 2001-05-10 | Schering Ag | Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR) |
| FR2807767B1 (fr) | 2000-04-12 | 2005-01-14 | Lab Francais Du Fractionnement | Anticorps monoclonaux anti-d |
| US7442777B2 (en) * | 2000-11-29 | 2008-10-28 | Arius Research Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD63 |
| US8231878B2 (en) * | 2001-03-20 | 2012-07-31 | Cosmo Research & Development S.P.A. | Receptor trem (triggering receptor expressed on myeloid cells) and uses thereof |
| US8981061B2 (en) | 2001-03-20 | 2015-03-17 | Novo Nordisk A/S | Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof |
| US8088387B2 (en) | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
| US8399618B2 (en) | 2004-10-21 | 2013-03-19 | Xencor, Inc. | Immunoglobulin insertions, deletions, and substitutions |
| US20070213660A1 (en) | 2004-10-29 | 2007-09-13 | Mark Richards | Fibrin sealant delivery device including pressure monitoring, and method and kits thereof |
| AU2006230413B8 (en) | 2005-03-31 | 2011-01-20 | Xencor, Inc | Fc variants with optimized properties |
| WO2006138005A2 (en) | 2005-05-10 | 2006-12-28 | Monsanto Technology, Llc | Genes and uses for plant improvement |
| ES2547463T3 (es) | 2005-06-17 | 2015-10-06 | Merck Sharp & Dohme Corp. | Moléculas de unión a ILT3 y usos de las mismas |
| US20090202544A1 (en) * | 2006-02-02 | 2009-08-13 | The Trustees Of Columbia University In The City Of New York | Methods of Treating Diseases by Targeting Silt3 |
| WO2008094176A2 (en) | 2006-06-19 | 2008-08-07 | Tolerx, Inc. | Ilt3 binding molecules and uses therefor |
| EP2535354B1 (en) * | 2007-06-18 | 2017-01-11 | Merck Sharp & Dohme B.V. | Antibodies to human programmed death receptor pd-1 |
| WO2011116299A2 (en) | 2010-03-18 | 2011-09-22 | Colorado State University Research Foundation | Myeloid derived suppressor cell inhibiting agents |
| RS58810B1 (sr) | 2009-06-03 | 2019-07-31 | Immunogen Inc | Metodi konjugacije |
| SI2506871T1 (sl) | 2009-11-30 | 2016-12-30 | Janssen Biotech, Inc. | Mutanti Fc protitelesa z odstranjenimi efektorskimi funkcijami |
| AU2010339359A1 (en) | 2009-12-29 | 2012-07-26 | Kyowa Hakko Kirin Co., Ltd. | Anti-CD27 antibody |
| US20110262348A1 (en) | 2010-03-29 | 2011-10-27 | Vrije Universiteit Brussel | Selective targeting of intratumoral cells |
| JP2013523098A (ja) | 2010-03-29 | 2013-06-17 | ザイムワークス，インコーポレイテッド | 強化又は抑制されたエフェクター機能を有する抗体 |
| WO2012031008A2 (en) * | 2010-08-31 | 2012-03-08 | The General Hospital Corporation | Cancer-related biological materials in microvesicles |
| US8427899B2 (en) * | 2010-10-29 | 2013-04-23 | Taiwan Semiconductor Manufacturing Company, Ltd. | Self-adaptive sensing design |
| HUE041335T2 (hu) | 2011-03-29 | 2019-05-28 | Roche Glycart Ag | Antitest FC-variánsok |
| CN109517897A (zh) * | 2011-04-28 | 2019-03-26 | 南加利福尼亚大学 | 人类髓源抑制性细胞癌症标记 |
| US9696312B2 (en) | 2011-09-02 | 2017-07-04 | The Trustees Of Columbia University In The City Of New York | Diagnosis and treatment of cancer expressing ILT3 or ILT3 ligand |
| CA2877081C (en) | 2011-09-27 | 2020-09-22 | The Governing Council Of The University Of Toronto | Molecular display method |
| EP2855526B1 (en) * | 2012-05-24 | 2018-11-07 | VIB vzw | Anti-macrophage mannose receptor immunoglobulin single variable domains for targeting and in vivo imaging of tumor-associated macrophages |
| WO2014025828A1 (en) | 2012-08-06 | 2014-02-13 | The Regents Of The University Of California | Engineered antibody fragments for targeting and imaging cd8 expression in vivo |
| TWI589590B (zh) | 2012-11-07 | 2017-07-01 | 輝瑞股份有限公司 | 抗切口３（ａｎｔｉ-ｎｏｔｃｈ３）抗體及抗體-藥物共軛體 |
| WO2014074942A1 (en) | 2012-11-08 | 2014-05-15 | Illumina, Inc. | Risk variants of alzheimer's disease |
| CA2894879A1 (en) * | 2012-12-19 | 2014-06-26 | Amplimmune, Inc. | B7-h4 specific antibodies, and compositions and methods of use thereof |
| US9617266B2 (en) * | 2013-03-05 | 2017-04-11 | Merck Patent Gmbh | Imidazopyrimidine derivatives |
| GB201311487D0 (en) | 2013-06-27 | 2013-08-14 | Alligator Bioscience Ab | Bispecific molecules |
| WO2015035365A1 (en) * | 2013-09-09 | 2015-03-12 | The Nohns Hopkins University | Targeting the m2-tumor associated macrophage for cancer therapy |
| RU2016129959A (ru) * | 2013-12-30 | 2018-02-02 | Эпимаб Биотерепьютикс Инк. | Иммуноглобулин с тандемным расположением fab-фрагментов и его применение |
| US20170240631A1 (en) * | 2014-08-08 | 2017-08-24 | Alector Llc | Anti-trem2 antibodies and methods of use thereof |
| CA2961950A1 (en) | 2014-09-28 | 2016-03-31 | The Regents Of The University Of California | Modulation of stimulatory and non-stimulatory myeloid cells |
| WO2016064895A1 (en) | 2014-10-20 | 2016-04-28 | The Brigham And Women's Hospital, Inc. | Targeting apolipoprotein e (apoe) in neurologic disease |
| EP3237450B1 (en) * | 2014-12-22 | 2021-03-03 | The Rockefeller University | Anti-mertk agonistic antibodies and uses thereof |
| WO2017058866A1 (en) | 2015-09-28 | 2017-04-06 | Precision Immune, Inc. | Anti-trem2 antibodies and uses thereof |
| US20190330335A1 (en) | 2015-10-06 | 2019-10-31 | Alector Llc | Anti-trem2 antibodies and methods of use thereof |
| AU2017300040A1 (en) | 2016-07-22 | 2019-01-24 | Deutsches Zentrum Für Neurodegenerative Erkrankungen E.V. (Dzne) | TREM2 cleavage modulators and uses thereof |
| US10167796B2 (en) | 2017-05-17 | 2019-01-01 | GM Global Technology Operations LLC | Gasoline particulate filter regeneration strategy |
| JP2020530986A (ja) | 2017-07-27 | 2020-11-05 | ノバルティス アーゲー | シェダーゼ耐性ｔｒｅｍ２変異体 |
| DK3601358T5 (da) | 2017-08-03 | 2024-09-02 | Alector Llc | Anti-trem2-antistoffer og fremgangsmåder til anvendelse deraf |
| WO2019055841A1 (en) | 2017-09-14 | 2019-03-21 | Denali Therapeutics Inc. | ANTI-TREM2 ANTIBODIES AND METHODS OF USE |
| KR102860409B1 (ko) | 2017-12-12 | 2025-09-16 | 파이오니어 임뮤노테라퓨틱스, 인코퍼레이티드 | 항-trem2 항체 및 관련 방법 |
| CA3120875A1 (en) | 2018-12-11 | 2020-06-18 | Pionyr Immunotherapeutics, Inc. | Methods of using anti-trem2 antibodies |
-
2015
- 2015-09-28 CA CA2961950A patent/CA2961950A1/en active Pending
- 2015-09-28 KR KR1020177011420A patent/KR102506663B1/ko active Active
- 2015-09-28 WO PCT/US2015/052682 patent/WO2016049641A1/en not_active Ceased
- 2015-09-28 US US15/514,471 patent/US10428143B2/en active Active
- 2015-09-28 EP EP15844518.9A patent/EP3197495A4/en active Pending
- 2015-09-28 KR KR1020247012684A patent/KR20240056629A/ko active Pending
- 2015-09-28 KR KR1020237007310A patent/KR102659538B1/ko active Active
- 2015-09-28 MX MX2017004007A patent/MX388410B/es unknown
- 2015-09-28 IL IL283834A patent/IL283834B/en unknown
- 2015-09-28 IL IL312777A patent/IL312777A/en unknown
- 2015-09-28 EA EA201790755A patent/EA034921B1/ru unknown
- 2015-09-28 JP JP2017516664A patent/JP6811711B2/ja active Active
- 2015-09-28 CN CN201580064906.2A patent/CN106999585A/zh active Pending
- 2015-09-28 AU AU2015319809A patent/AU2015319809B2/en active Active
- 2015-09-28 IL IL294043A patent/IL294043B2/en unknown
-
2017
- 2017-03-08 ZA ZA2017/01658A patent/ZA201701658B/en unknown
- 2017-03-08 IL IL251020A patent/IL251020B/en active IP Right Grant
- 2017-03-27 MX MX2021014448A patent/MX2021014448A/es unknown
-
2019
- 2019-07-01 US US16/459,589 patent/US11325973B2/en active Active
-
2020
- 2020-01-30 AU AU2020200678A patent/AU2020200678B2/en active Active
- 2020-12-15 JP JP2020207244A patent/JP7168641B2/ja active Active
-
2022
- 2022-04-05 US US17/714,051 patent/US20220411496A1/en active Pending
- 2022-04-26 AU AU2022202730A patent/AU2022202730B2/en active Active
- 2022-10-27 JP JP2022172033A patent/JP7668257B2/ja active Active
-
2024
- 2024-11-26 JP JP2024205131A patent/JP2025027013A/ja active Pending